Russia has announced the rollout of its first cancer vaccine, which will be provided to patients free of charge after demonstrating strong results in preclinical trials.
The breakthrough treatment, initially developed to fight colorectal cancer, showed remarkable efficacy in reducing tumour size and slowing disease progression. According to research data, tumour growth was reduced by 60% to 80%, while survival rates improved significantly. Importantly, repeated administration of the vaccine was found to be safe, with no adverse effects reported.
Encouraged by these results, Russian scientists are also advancing vaccine research for other aggressive cancers, including glioblastoma and melanoma.
Unlike traditional vaccines that prevent infections such as measles or chickenpox, cancer vaccines are designed to train the immune system to recognise and attack malignant cells. The American Cancer Society notes that while vaccines for certain cancers—such as prostate and bladder—already exist, global research efforts are accelerating to expand their use.
Cancer vaccines are typically laboratory-made substances that boost the body’s natural defences. Some are designed to prevent cancers caused by viruses, like the HPV vaccine, while others—such as Russia’s newly unveiled treatment—are developed as therapies to directly target existing tumours.
The rollout marks a significant milestone in oncology, giving new hope to patients and pushing the frontiers of cancer treatment worldwide.
